RxDoctor Payments Data

Preeti Narayan, MD

Interventional Pain Medicine · Marietta, GANPI 1093155970

Payments from drug & device makers

$4,599in general payments, 2019–2025

Across 109 payments — averaging $42.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$648
  • Nevro Corp.$561
  • Biotronik NRO, Inc.$180
  • Curonix LLC$144
  • Nalu Medical, Inc.$112
  • plus $672 from 18 others
$590in research payments, 2019–2025

Across 2 payments — averaging $295.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nevro Corp.$590

What the payments were for

  • Travel & lodging$78417%
  • Food & beverage$3,76382%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,599 in reported general payments places this provider in the 45th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$92,346
Medicare patients
186
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine50$13,224
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen554$12,010
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen369$9,263
BelbucaBuprenorphine Hcl12$7,434
Xtampza ErOxycodone Myristate15$6,862
Fentanyl32$3,244
Oxycodone Hcl111$2,055
Morphine Sulfate ErMorphine Sulfate53$1,632
Gabapentin83$758
Tramadol Hcl76$606
Methadone Hcl35$567
Pregabalin23$426
Acetaminophen-CodeineAcetaminophen With Codeine23$295
Baclofen14$175
Cyclobenzaprine Hcl33$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$82$14,29627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 129 interventional pain medicine providers in Georgia.

Other interventional pain medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →